GLP-1 'don't do what I do' TikTok: what the science says

What did @charitykface actually say?

The entire transcript is three sentences: "Is it worth it? Oh yeah, it's worth it. If you're strong enough." That's it. There's no specific drug named, no dose mentioned, no side effects described. What we have is a vague endorsement of GLP-1 therapy with a caveat that effectiveness depends on personal "strength." The caption adds a self-deprecating note: "Don't do what I do though." So she's simultaneously recommending and warning against her own approach. That's worth pulling apart.

The video tells us almost nothing clinical, which makes it hard to fact-check in a traditional sense. But the framing, that GLP-1 therapy is a test of personal fortitude, carries real implications about who is and isn't "strong enough" to use these medications. That framing deserves scrutiny.

Does the science back this up?

Partially, but not in the way she implies. GLP-1 receptor agonists do require behavioral engagement to get the most out of them, but framing this as needing to be "strong enough" misrepresents what the research actually shows about who benefits.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide produced an average 20.9% body weight reduction over 72 weeks, with results that were largely consistent across participants regardless of baseline behavioral factors. Similarly, the STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced roughly 14.9% mean weight loss. Neither trial stratified outcomes primarily by psychological resilience or "strength." The medications work through appetite suppression and hormonal signaling, not through willpower amplification. Suggesting otherwise sets up patients for self-blame if results are modest.

What did they get wrong (or right)?

She got one thing right: GLP-1 therapy does involve tradeoffs that not everyone finds manageable. Nausea, vomiting, constipation, and fatigue are real and documented, affecting between 40-80% of users depending on the agent and dose (Davies et al., 2021, Lancet). Some people do stop treatment because the side effect burden outweighs the benefit for them. In that narrow sense, tolerating the process does require persistence.

But "strong enough" as a framework is misleading. It implies that people who discontinue or don't respond well lacked character. That's not supported by evidence. GLP-1 non-response has biological underpinnings, including receptor expression variability and gut motility differences, that have nothing to do with mental fortitude. The American Diabetes Association standards of care emphasize that treatment selection should be individualized based on clinical profile, not personal grit. Framing dropout as a failure of strength is both inaccurate and potentially harmful to people who are already struggling.

What should you actually know?

GLP-1 receptor agonists are among the most studied weight management interventions available right now, and the efficacy data is genuinely strong. But they are not a personality test. Side effect profiles vary significantly between liraglutide, semaglutide, and tirzepatide. Dose titration protocols exist specifically to improve tolerability, and working with a clinician to adjust timing, dose escalation pace, or anti-nausea strategies can make a substantial difference.

The caption "Don't do what I do though" is actually the most honest part of this video. It signals she may be self-managing in ways that aren't recommended, possibly skipping doses, using informal sourcing, or ignoring side effects. None of that is a model to follow. If you're considering a GLP-1 therapy, the path forward is through a licensed provider who can evaluate your full medical history, not through emulating someone's unspecified personal routine on TikTok.

• Side effects are manageable with proper titration, not by being "stronger"
• Non-response or discontinuation is not a character flaw
• A provider-supervised approach significantly changes outcomes